세계의 박테리오파지 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Bacteriophage Therapy Market is presumed to reach the market size of nearly USD 74.28 Million by 2032 from USD 47.39 Million in 2023 with a CAGR of 5.12% under the study period 2024-2032.

Bacteriophage therapy or phage therapy utilizes bacteriophages to treat bacterial infections. Bacteriophage or phage is the type of virus that gets attached to the bacterial cell and injects viral genome or DNA into the bacterial cell. The viral genome takes the place of the bacterial genome and eventually stops further bacterial growth and infection. The bacterial cell with viral genome replicates bacteriophages. Bacteriophages are compared with antibiotics as both effectively kill infection-causing bacteria; however, bacteriophages are more specific in action than antibiotics. They do not harm host cells as well as to other beneficial bacteria such as gut flora in the host body. Bacteriophages are an alternative therapy to antibiotics as many infectious bacteria are now resistant to the regularly used broad-spectrum antibiotics.

MARKET DYNAMICS

The factors that are driving the global bacteriophage market are the increasing prevalence of air, water, and foodborne bacterial infection, and increasing incidences of antibiotic resistance. Besides, there are almost nil or few side effects of bacteriophage therapy. This factor is supporting the global market. Moreover, extensive R & D on bacteriophage therapy by private as well as government sectors is further fuelling the global market. During the COVID-19 pandemic, the bacteriophage therapy market is likely to expand as the entire global focus is on the development of new treatment therapies for infections.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Bacteriophage Therapy. The growth and trends of Bacteriophage Therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Bacteriophage Therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Phage Probiotics
• Phage Therapeutic

By Route of Administration

• Oral
• Topical

By Application

• Skin Infection Treatment
• Gastroenterology
• Wound Prophylaxis
• Respiratory Infections Treatment
• Urogenital Infection Treatment

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Bacteriophage Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Bacteriophage Therapy market include PhagePro Inc., Enbiotix Inc., TechnoPhage SA, Eligo Bioscience SA, Armata Pharmaceuticals Inc., ContraFect Corporation, Phagomed Biopharma GmbH., Eliava Biopreparations Ltd., Fixed-Phage Ltd., Intodeworld Inc., Pherecydes Pharma, BiomX Ltd., Adaptive Phage Therapeutics, Intralytix Inc., Phagelux Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. BACTERIOPHAGE THERAPY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Route of Administration
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL BACTERIOPHAGE THERAPY MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Product
• 5.4. Phage Probiotics Historic and Forecast Sales By Regions
• 5.5. Phage Therapeutic Historic and Forecast Sales By Regions

6. GLOBAL BACTERIOPHAGE THERAPY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1. Overview By Route of Administration
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Route of Administration
• 6.4. Oral Historic and Forecast Sales By Regions
• 6.5. Topical Historic and Forecast Sales By Regions

7. GLOBAL BACTERIOPHAGE THERAPY MARKET ANALYSIS BY APPLICATION

• 7.1. Overview By Application
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Application
• 7.4. Skin Infection Treatment Historic and Forecast Sales By Regions
• 7.5. Gastroenterology Historic and Forecast Sales By Regions
• 7.6. Wound Prophylaxis Historic and Forecast Sales By Regions
• 7.7. Respiratory Infections Treatment Historic and Forecast Sales By Regions
• 7.8. Urogenital Infection Treatment Historic and Forecast Sales By Regions

8. GLOBAL BACTERIOPHAGE THERAPY MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE BACTERIOPHAGE THERAPY COMPANIES

• 9.1. Bacteriophage Therapy Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF BACTERIOPHAGE THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. PhagePro Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Enbiotix Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. TechnoPhage SA
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Eligo Bioscience SA
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Armata Pharmaceuticals Inc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. ContraFect Corporation
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Phagomed Biopharma GmbH.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Eliava Biopreparations Ltd.
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Fixed-Phage Ltd.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Intodeworld Inc.
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Pherecydes Pharma
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. BiomX Ltd.
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments
• 10.15. Adaptive Phage Therapeutics
  • 10.15.1 Company Overview
  • 10.15.2 Company Revenue
  • 10.15.3 Products
  • 10.15.4 Recent Developments
• 10.16. Intralytix Inc.
  • 10.16.1 Company Overview
  • 10.16.2 Company Revenue
  • 10.16.3 Products
  • 10.16.4 Recent Developments
• 10.17. Phagelux Inc
  • 10.17.1 Company Overview
  • 10.17.2 Company Revenue
  • 10.17.3 Products
  • 10.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies